CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
CVHLV194fs (c.581_582del)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseKlein et al., 2001
CVHLA149fs (c.449del14-nt)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseKlein et al., 2001
CVHLR167W (c.499C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseErlic et al., 2010
CVHLR161* (c.481C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseCybulski et al., 2002
CVHLNull (Partial deletion of Exons 2 & 3)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseBenhammou et al., 2010
BRRM1UnderexpressionPredictiveSupportsSensitivity/ResponsePancreatic CancerGemcitabineAkita et al., 2009
BRRM1UnderexpressionPredictiveSupportsSensitivity/ResponsePancreatic CancerGemcitabineNakahira et al., 2007
CVHLF136S (c.407T>C)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseRocha et al., 2003
CVHLP146fs (c.437del)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseRocha et al., 2003
CVHLR167W (c.499C>T)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseRocha et al., 2003
CVHLR167Q (c.500G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseRocha et al., 2003
CVHLS80R (c.238A>C)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseRocha et al., 2003
CVHLS80R (c.238A>C)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseRocha et al., 2003
CVHLW88R (c.262T>C)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseRocha et al., 2003
CVHLE94* (c.280G>T)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseRocha et al., 2003
CVHLH115fs (c.344del)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseRocha et al., 2003
CVHLP102fs (c.305delC)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseRocha et al., 2003
CVHLE94* (c.280G>T)PredisposingN/AVon Hippel-Lindau DiseaseSun et al., 2012
CVHLY175N (c.523T>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseRuiz-Llorente et al., 2004
CVHLY175C (c.524A>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseRuiz-Llorente et al., 2004
CVHLD121G (c.362A>G)PredisposingN/AVon Hippel-Lindau DiseaseRuiz-Llorente et al., 2004
CVHLS65L (c.194C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseRuiz-Llorente et al., 2004
CVHLQ96* (c.286C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseRuiz-Llorente et al., 2004
BRRM1UnderexpressionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGemcitabine,Paclitaxel,VinorelbineVilmar et al., 2013
CVHLSplice Site (c.463+2T>C)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseJilg et al., 2012
CVHLR82_V84del (c.243_251del)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseCrossey et al., 1994
CVHLP40fs (c.118ins)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseCrossey et al., 1994
CVHLT152fs (c.455insA)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseCrossey et al., 1994
CVHLT157fs (c.472ins)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseCrossey et al., 1994
CVHLF76del (c.227_229del)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseCrossey et al., 1994
CVHLSplice Site (c.464-1G>T)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseCrossey et al., 1994
CVHLR177fs (c.528del)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseCrossey et al., 1994
CVHLG93_Y98del (c.275_292del)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseStolle et al., 1998
CVHLF76del (c.227_229del)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseStolle et al., 1998
CVHLE160fs (c.477del)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseStolle et al., 1998
BARID1AUnderexpressionPrognosticSupportsPoor OutcomeClear Cell Renal Cell CarcinomaPark et al., 2015
CVHLA149S (c.445G>T)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseMete et al., 2014
CVHLQ195* (c.583C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseLosonczy et al., 2013
CVHLS65W (c.194C>G)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseWu et al., 2013
CVHLS65FS (c.194delC)PredisposingN/AVon Hippel-Lindau DiseaseOng et al., 2007
CVHLQ73fs (c.214insGCCC)PredisposingN/AVon Hippel-Lindau DiseaseOng et al., 2007
CVHLH125fs (c.374insA)PredisposingN/AVon Hippel-Lindau DiseaseOng et al., 2007
CVHLT152fs (c.455insA)PredisposingN/AVon Hippel-Lindau DiseaseOng et al., 2007
CVHLK159fs (c.474_476delGAAinsC)PredisposingN/AVon Hippel-Lindau DiseaseOng et al., 2007
CVHLY175* (c.525delC)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseOng et al., 2007
CVHLD197FS (c.589delG)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseOng et al., 2007
CVHLT202fs (c.606insA)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseOng et al., 2007
CVHLR113FS (c.337delC)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseOng et al., 2007
CVHLA56fs (c.166dup)PredisposingN/AVon Hippel-Lindau DiseaseOng et al., 2007
CVHLF76del (c.227_229del)PredisposingN/AVon Hippel-Lindau DiseaseOng et al., 2007
Page 49 of 96